Posted by Michael Wonder on 06 Jun 2024
Ivonescimab in combination with chemotherapy approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A clinical trial: positive trend observed in overall survival towards ivonescimab plus chemotherapy
31 May 2024 - Separate and distinct from HARMONi-2 announcement, HARMONi-A showed clinically meaningful and statistically significant benefit: progression-free survival hazard ratio of 0.46.
Summit Therapeutics announced that, on 24 May 2024, our partner, Akeso received marketing authorisation in China from the National Medical Products Administration.
